BC Innovations | Feb 12, 2019
Distillery Therapeutics


INDICATION: Depression; neurology In silico , cell culture and rat studies identified a methanamine-based agonist of 5-HT1A receptor that could help treat depression and other neuropsychiatric diseases. Chemical synthesis, cell-based screening of methanamine analogs in binding...
BC Week In Review | Oct 7, 2013
Company News

Pierre Fabre, Neurolixis deal

Pierre Fabre's Pierre Fabre Medicament division granted Neurolixis exclusive, worldwide rights to develop and commercialize serotonergic compounds F15599 and befiradol. F15599 has completed one Phase I trial and befiradol has completed Phase II testing with...
Items per page:
1 - 2 of 2